Description
MGCD-265 Analog is an inhibitor of MET that may exhibit anticancer potential.
MGCD-265 Analog
Product ID M2408
Cas No. 875337-44-3
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 875337-44-3 |
|---|---|
| Purity | ≥98% |
| Formula | C26H20FN5O2S2 |
| Formula Wt. | 517.60 |
| Chemical Name | N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide |
| IUPAC Name | N-[[3-fluoro-4-[2-(1-methylimidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-phenylacetamide |
| Synonym | MGCD-265; MGCD265; MGCD 265 Analog, MGCD265 Analog, MGCD-265 Analog, Glesatinib Analog |
| Solubility | DMSO 104 mg/mL (200.92 mM) Water Insoluble Ethanol Insoluble |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Belalcazar A1, Azaña D, Perez CA, et al. Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther. 2012 Apr;12(4):519-28. PMID: 22500688.